ERBB2 and non-small cell lung carcinoma: There are also results indicating the use of molecular targeting agents through proper dose and administration are effective for treating LMC in selected patient subgroups (EGFR TKI in EGFR-mutated NSCLC, intrathecal trastuzumab in HER2 positive breast cancer, and intrathecal rituximab in CD20 positive lymphoma).